Biotech startup NewLimit, co-founded by Coinbase CEO Brian Armstrong, has secured a $130 million Series B to develop treatments that could reverse cellular aging.
The round was led by Kleiner Perkins, with participation from Nat Friedman, Daniel Gross, Khosla Ventures, and returning investors like Founders Fund, Garry Tan, Patrick Collison, and others.
Founded in 2021 by Brian Armstrong, former GV partner Blake Byers, and stem cell researcher Jacob Kimmel, NewLimit is pioneering the use of epigenetic reprogramming to restore youthful functions in aged human cells.
From simulation to lab: AI meets anti-aging drug discovery
NewLimit’s current focus is on developing medicines that can rejuvenate liver cells. According to Kimmel, lab tests show early success — treated liver cells began behaving more like those from younger donors, improving fat and alcohol metabolism.
What sets NewLimit apart is its AI-driven discovery process. The team uses machine learning to simulate drug interactions at scale, testing only the most promising candidates in the lab. This “lab-in-a-loop” approach accelerates research while improving precision, allowing the AI model to evolve based on real-world outcomes.
Advertisement
Human trials still years away
Despite promising preclinical results, NewLimit is several years from human trials. The new funding will support continued drug discovery and laboratory validation of AI-generated candidates.
Joining a growing field of longevity startups
NewLimit joins a wave of high-profile longevity companies. Competitor Retro Biosciences raised $180M from OpenAI’s Sam Altman and is now reportedly pursuing a $1B Series A, while Altos Labs, backed by Jeff Bezos, launched with $3B in funding.
With $130M in fresh capital, NewLimit is positioning itself at the frontier of a booming longevity biotech sector, aiming to extend not just lifespan—but healthspan.
